NCT07168226 - Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101 | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

July 31, 2027

Conditions

Cachexia; Cancer

Interventions

DRUG

Active Comparator

Megace F suspension 20mL, intake daily for 12weeks

DRUG

ASCA101 24.32mg/kg

ASCA101 Inj. 24.32mg/kg, twice a week for 12 weeks

DRUG

ASCA101 32.43mg/kg

ASCA101 Inj. 32.43mg/kg, twice a week for 12 weeks

DRUG

Placebo

0.9% normal saline injection

Trial Locations (6)

Samsung Medical Center, Seoul

National Cancer Center, Gyeonggi-do

Chung-Ang University Gwangmyeong Hospital, Gyeonggi-do

Seoul ST. Mary's hospital, Seoul

Korea University Anam Hospital, Seoul

Ajou University Hospital, Gyeonggi-do